p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
about
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancerSequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.Epigenetic therapies in MDS and AMLDecitabine in the treatment of myelodysplastic syndromes.Leukaemogenesis: more than mutant genesThe effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines.Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromesThe depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progressionp53R2 expression as a prognostic biomarker in early stage non-small cell lung cancerSynergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.The myelodysplastic syndrome as a prototypical epigenetic diseaseDifferential Expressions of p53, p53R2, hRRM2 and PBR in Chronic Lymphocytic Leukemia: A Correlation with Intracellular Cholesterol.5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.Older patients with acute myeloid leukemia.Thiosemicarbazones: the new wave in cancer treatment.Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies.Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latencyThe role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of CancerCombined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytesHigh DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.Differential expression profile analysis of DNA damage repair genes in CD133+/CD133- colorectal cancer cells.Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.The association between non-Hodgkin lymphoma and methylation of p73.
P2860
Q24642847-99265FD8-BE59-40F8-83F8-705C82DE66CEQ31149399-84542FBD-029C-4E6B-BF3D-02F1BF9EE0E3Q33863567-4B3D07F6-F393-4EDA-8684-254D3978F96CQ34088403-BA096B34-B717-436E-8254-9AF3DB81C291Q34275371-1541B80C-2BF0-448E-A129-380B9C97B7EBQ34336372-420E8A97-2ECF-4955-8A80-E110445A0B6AQ35087659-8E5BF847-964E-4946-B4D7-DDF9E68698C0Q35985465-65FE5D1A-49D9-449E-9D35-50FDA5A2C796Q36216571-EE15CBB7-7AB5-404F-8826-B2EBE52D2F6EQ36275976-BF517ED2-B247-484D-B5D5-3F3D157690BAQ36833557-D4325700-C155-4F88-8625-577A9F841308Q37013007-6F150EA1-F1AA-4FE5-8497-EC21243AA562Q37601778-C3D83290-5134-4671-8061-7F3ACA25EA53Q37810969-E3B25468-82EA-4521-9892-46FBF580E63EQ37855829-80459BE8-D2AA-4751-86F0-C69C0FB467E2Q38089064-A1A74F3F-2818-4AA3-BF05-3CE50D8006BEQ38098179-B538FF83-304C-4EDE-9082-30450C5401C1Q38160051-DAC9C515-EE19-48A0-ACD3-FBA6A693954FQ38696769-CD06A68B-9194-4E1E-B193-6D452F9F591AQ39100888-E37102EE-BA4A-4FA6-A801-BA29A189A519Q39768618-3A8679CA-A1F5-4291-9DCF-3BBF19F760A3Q41144456-A7DCD003-9600-4DA1-B62E-E86D798B6DB5Q42107433-B08D1DD3-26CD-4791-8400-D263780EA3A6Q47156483-47C25DA5-AE66-4E5C-96A1-D363FA7F6DF5Q47296951-382B3DF3-0920-433B-A2A9-210A91375BE5Q54356009-F2BFCE6B-68C7-4FA0-927D-BB1D9A1055F2
P2860
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
p53-inducible ribonucleotide r ...... me/acute myelogenous leukemia.
@en
p53-inducible ribonucleotide reductase
@nl
type
label
p53-inducible ribonucleotide r ...... me/acute myelogenous leukemia.
@en
p53-inducible ribonucleotide reductase
@nl
prefLabel
p53-inducible ribonucleotide r ...... me/acute myelogenous leukemia.
@en
p53-inducible ribonucleotide reductase
@nl
P2093
P2860
P1433
P1476
p53-inducible ribonucleotide r ...... me/acute myelogenous leukemia.
@en
P2093
Adam R Karpf
David A Jones
Maria R Baer
Petra A Link
Smitha R James
P2860
P304
P356
10.1158/0008-5472.CAN-08-1860
P407
P577
2008-11-01T00:00:00Z